• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[骨质疏松症的长期治疗理念]

[Long-term treatment concepts for osteoporosis].

作者信息

Obermayer-Pietsch Barbara, Fössl Ines, Dimai Hans Peter

机构信息

Klin. Abteilung Endokrinologie und Diabetologie, Univ. Klinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich.

出版信息

Internist (Berl). 2021 May;62(5):474-485. doi: 10.1007/s00108-021-00993-3. Epub 2021 Mar 12.

DOI:10.1007/s00108-021-00993-3
PMID:33710362
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8079292/
Abstract

The need for a long-term pharmacological treatment of osteoporosis, the problem of potential compliance issues and also potentially severe side effects during the treatment are of central interest not only for patients but also for medical guidelines and prescribers. This review summarizes the current knowledge about the pharmacological substances used and the current scientifically based guidelines and approaches for the long-term use as well as the monitoring and potential treatment changes with a special focus on future developments.

摘要

骨质疏松症长期药物治疗的必要性、潜在的依从性问题以及治疗期间可能出现的严重副作用，不仅是患者关注的核心问题，也是医学指南制定者和开处方者关注的核心问题。本综述总结了目前关于所用药物物质的知识，以及当前基于科学的长期使用指南和方法，以及监测和潜在的治疗调整，并特别关注未来的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/8079292/635254118652/108_2021_993_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/8079292/b71cb66154a6/108_2021_993_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/8079292/635254118652/108_2021_993_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/8079292/b71cb66154a6/108_2021_993_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b662/8079292/635254118652/108_2021_993_Fig2_HTML.jpg

相似文献

1
[Long-term treatment concepts for osteoporosis].[骨质疏松症的长期治疗理念]
Internist (Berl). 2021 May;62(5):474-485. doi: 10.1007/s00108-021-00993-3. Epub 2021 Mar 12.
2
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.乳腺癌幸存者关怀：长期医疗问题与生活方式建议的全面综述
Perm J. 2015 Spring;19(2):48-79. doi: 10.7812/TPP/14-241.
3
Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.持续使用双膦酸盐治疗骨质疏松症：探寻问题根源。
Am J Med. 2006 Apr;119(4 Suppl 1):S12-7. doi: 10.1016/j.amjmed.2005.12.018.
4
[Which adjuvant measures should be associated with long-term oral corticosteroid therapy in inflammatory diseases? A summary of existing French recommendations].
Rev Med Interne. 2021 Sep;42(9):616-624. doi: 10.1016/j.revmed.2021.03.326. Epub 2021 Jun 18.
5
Improving compliance and persistence with bisphosphonate therapy for osteoporosis.提高骨质疏松症双膦酸盐治疗的依从性和持续性。
Am J Med. 2006 Apr;119(4 Suppl 1):S18-24. doi: 10.1016/j.amjmed.2005.12.019.
6
Adverse effects of media reports on the treatment of osteoporosis.媒体报道对骨质疏松症治疗的不良影响。
J Endocrinol Invest. 2018 Dec;41(12):1359-1364. doi: 10.1007/s40618-018-0898-9. Epub 2018 May 14.
7
Prevention and treatment of glucocorticoid-induced osteoporosis in daily dermatologic practice.日常皮肤科实践中糖皮质激素诱导性骨质疏松症的防治
Int J Dermatol. 2008 Jul;47(7):737-42. doi: 10.1111/j.1365-4632.2008.03679.x.
8
The impact of expressions of treatment efficacy and out-of-pocket expenses on patient and physician interest in osteoporosis treatment: implications for pay-for-performance programs.治疗效果表达及自付费用对患者和医生参与骨质疏松症治疗的兴趣的影响：对按绩效付费计划的启示
J Gen Intern Med. 2008 Feb;23(2):164-8. doi: 10.1007/s11606-007-0490-z. Epub 2007 Dec 28.
9
[Glucocorticoid induced osteoporosis].[糖皮质激素性骨质疏松症]
Orthopade. 2007 Apr;36(4):381-8; quiz 389-90.
10
Is enough attention being given to the adverse effects of corticosteroid therapy?对于皮质类固醇疗法的副作用是否给予了足够的关注？
J Clin Pharm Ther. 2000 Jun;25(3):227-34. doi: 10.1046/j.1365-2710.2000.00284.x.

引用本文的文献

1
Does adding exercise or physical activity to pharmacological osteoporosis therapy in patients with increased fracture risk improve bone mineral density and lower fracture risk? A systematic review and meta-analysis.在骨折风险增加的患者中，将运动或体力活动添加到骨质疏松症药物治疗中是否能提高骨密度并降低骨折风险？系统评价和荟萃分析。
Osteoporos Int. 2023 Nov;34(11):1867-1880. doi: 10.1007/s00198-023-06829-0. Epub 2023 Jul 11.

本文引用的文献

1
Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.地诺单抗治疗中断的骨折风险与管理：欧洲钙化组织协会的系统评价与立场声明
J Clin Endocrinol Metab. 2020 Oct 26. doi: 10.1210/clinem/dgaa756.
2
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis.更新的骨质疏松症药物成本效益分析的系统评价。
Pharmacoeconomics. 2021 Feb;39(2):181-209. doi: 10.1007/s40273-020-00965-9. Epub 2020 Oct 7.
3
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
非典型股骨骨折风险与双膦酸盐预防脆性骨折。
N Engl J Med. 2020 Aug 20;383(8):743-753. doi: 10.1056/NEJMoa1916525.
4
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs.抗骨质疏松药物的心血管安全性评估。
Drugs. 2020 Oct;80(15):1537-1552. doi: 10.1007/s40265-020-01364-2.
5
Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?绝经期激素治疗在绝经后骨质疏松症的治疗中有作用吗？
Osteoporos Int. 2020 Dec;31(12):2271-2286. doi: 10.1007/s00198-020-05497-8. Epub 2020 Jul 8.
6
Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.用成骨和抗吸收治疗治疗绝经后骨质疏松症：联合和序贯方法。
Bone. 2020 Oct;139:115516. doi: 10.1016/j.bone.2020.115516. Epub 2020 Jul 2.
7
Biological activity is not suppressed in mid-shaft stress fracture of the bowed femoral shaft unlike in "typical" atypical subtrochanteric femoral fracture: A proposed theory of atypical femoral fracture subtypes.与“典型”非典型转子下股骨骨折不同，弯曲股骨干中段应力性骨折中生物活性未受抑制：非典型股骨骨折亚型的一个理论假说。
Bone. 2020 Aug;137:115453. doi: 10.1016/j.bone.2020.115453. Epub 2020 May 26.
8
Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.非典型股骨骨折患者的医学管理：来自欧洲钙化组织协会的系统评价和建议。
J Clin Endocrinol Metab. 2020 May 1;105(5):1682-99. doi: 10.1210/clinem/dgz295.
9
Treatment of bone loss in proximal femurs of postmenopausal osteoporotic women with AGN1 local osteo-enhancement procedure (LOEP) increases hip bone mineral density and hip strength: a long-term prospective cohort study.AGN1 局部骨增强术（LOEP）治疗绝经后骨质疏松女性股骨近端骨丢失可增加髋部骨密度和髋部强度：一项长期前瞻性队列研究。
Osteoporos Int. 2020 May;31(5):921-929. doi: 10.1007/s00198-019-05230-0. Epub 2019 Dec 4.
10
Hip fractures following denosumab discontinuation: three clinical cases reports.地舒单抗停药后发生髋部骨折：三例临床病例报告。
J R Soc Med. 2019 Nov;112(11):472-475. doi: 10.1177/0141076819861027. Epub 2019 Sep 17.